TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT

Show other versions (1)

Systemic mastocytosis (SM) is a rare disease with a range of clinical presentations, and the vast majority of patients have a KIT D816V mutation that results in gain of function. The multikinase/KIT inhibitor midostaurin inhibits the D816V mutant, and has a well-established role in treatment of adv...

Full description

Bibliographic Details
Main Authors: Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni
Format: Article
Language:English
Published: PAGEPress Publications 2022-10-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
systemic mastocytosis
midostaurin
guidance
management
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/5042

Internet

https://www.mjhid.org/index.php/mjhid/article/view/5042

Similar Items